COMP <GO>
ULS vs ABBV // EV/EBITDA & P/E VALUATION
UL Solutions Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ULS 6
— ABBV 9
▲ EV/EBITDA & P/E VALUATION LEADER: ULS
LAST: $74.76 (-0.93%) • MKT CAP: $15.24B
valuation
22.4x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ULS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ULS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 49.50% | 70.20% | -20.70 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 28.30% | 29.00% | -0.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 22.4x | 33.3x | -10.90 | ULS | /valuation <GO> |
| Free Cash Flow Yield | 2.65% | 3.47% | -0.82 | ABBV | /fcf-yield <GO> |
| Operating Margin | 17.10% | 24.60% | -7.50 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 10.60% | 6.90% | +3.70 | ULS | /net-margins <GO> |
| Revenue Growth (YoY) | 6.40% | 8.60% | -2.20 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.68% | 2.27% | -1.59 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.58 | 5.33 | +2.25 | ULS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ULS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.40% | -0.20 | ULS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.1 | 72.8 | -11.70 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.15 | -0.07 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 43.6x | 113.1x | -69.50 | ULS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $15.24B | $513.86B | -$498.62B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ULS REV | ABBV REV | ULS GROSS % | ABBV GROSS % | ULS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.05B | $61.16B | 49.5% | 70.2% | $403.0M | $17.82B |
| FY 2024 | $2.87B | $56.33B | 48.5% | 70.0% | $287.0M | $17.83B |
| FY 2023 | $2.68B | $54.32B | 44.0% | 44.0% | $346.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ULS // BETA 1.08
ABBV // BETA 1.15